Prediction of protein degradation during vibrating mesh nebulization via a high throughput screening method

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 87, Issue 2, 2014, Pages 386-394

  Hertel, Sebastian ^a   Pohl, Thomas ^b   Friess, Wolfgang ^a   Winter, Gerhard ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b SuppreMol GmbH   (Germany)

Author keywords

Agitation; Biopharmaceuticals; Design of experiment; Fc RIIB receptor; Formulation development; PARI eFlow ; Protein stability; Screening method; Vibrating mesh nebulization

Indexed keywords

EXCIPIENT; FC RECEPTOR IIB; HISTIDINE; MANNITOL; SM 101; SODIUM CHLORIDE; SUCROSE; UNCLASSIFIED DRUG; FC RECEPTOR; FCGR3B PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN;

AEROSOL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG FORMULATION; DRUG STABILITY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MEDICAL NEBULIZER; NEBULIZATION; PROTEIN AGGREGATION; PROTEIN DEGRADATION; TEMPERATURE; CHEMISTRY; COMPARATIVE STUDY; DEVICES; DRUG DELIVERY SYSTEM; EQUIPMENT DESIGN; FEASIBILITY STUDY; HEAT; INHALATIONAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; NEBULIZER; PHARMACEUTICS; PROCEDURES; PROTEIN STABILITY; VIBRATION;

ADMINISTRATION, INHALATION; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; EXCIPIENTS; FEASIBILITY STUDIES; GPI-LINKED PROTEINS; HIGH-THROUGHPUT SCREENING ASSAYS; HOT TEMPERATURE; HUMANS; NEBULIZERS AND VAPORIZERS; PROTEIN STABILITY; PROTEOLYSIS; RECEPTORS, IGG; TECHNOLOGY, PHARMACEUTICAL; VIBRATION;

EID: 84902368367     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2014.03.020     Document Type: Article

References (40)

1. I. Gonda The ascent of pulmonary drug delivery J. Pharm. Sci. 89 2000 940 945
2. J.S. Patton Mechanisms of macromolecule absorption by the lungs Adv. Drug Deliv. Rev. 19 1996 3 36
3. A. Tronde, B. Nordén, H. Marchner, A.-K. Wendel, H. Lennernäs, and U.H. Bengtsson Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs J. Pharm. Sci. 92 2003 1216 1233
4. J.S. Patton, and P.R. Byron Inhaling medicines: delivering drugs to the body through the lungs Nat. Rev. Drug Discov. 6 2007 67 74
5. M. Bayat, and A.M. Cook Intrapulmonary administration of medications J. Neurosci. Nurs. 36 2004 231 235
6. Pulmozyme Worldwide Sales, Evaluate Ltd. < http://www.evaluategroup. com/Universal/View.aspx?type=Search&query=pulmozyme > (retrieved 12.02.13).
7. L. Guilleminault, V. Hervé-Grépinet, E. Lemarié, and N. Heuzé-Vourc'h The Airways: A Promising Route for the Pulmonary Delivery of Anticancer Agents 2012 InTech Riejka, Croatia
8. A.B. Watts, J.T. McConville, and R.O. Williams Current therapies and technological advances in aqueous aerosol drug delivery Drug Dev. Ind. Pharm. 34 2008 913 922
9. J.C. Johnson, J.C. Waldrep, J. Guo, and R. Dhand Aerosol Delivery of Recombinant Human DNase I: in Vitro Comparison of a Vibrating-Mesh Nebulizer With a Jet Nebulizer Respir. Care 53 2008 6
10. I. Fängmark, and J.C. Carpin Protein nebulization J. Aerosol Sci. 27 Suppl. 1 1996 S231 S232
11. R.W. Niven, A.Y. Ip, S.D. Mittelman, C. Farrar, T. Arakawa, and S.J. Prestrelski Protein nebulization: I. Stability of lactate dehydrogenase and recombinant granulocyte-colony stimulating factor to air-jet nebulization Int. J. Pharm. 109 1994 17 26
12. Y.-F. Maa, and C.C. Hsu Protein denaturation by combined effect of shear and air-liquid interface Biotechnol. Bioeng. 54 1997 503 512
13. R. Uchenna Agu, M. Ikechukwu Ugwoke, M. Armand, R. Kinget, and N. Verbeke The lung as a route for systemic delivery of therapeutic proteins and peptides Respir. Res. 2 2001 198 209
14. R.W. Niven Delivery of biotherapeutics by inhalation aerosol Crit. Rev.™ Therapeut. Drug Carrier Syst. 12 1995 151 231
15. A.Y. Ip, T. Arakawa, H. Silvers, C.M. Ransone, and R.W. Niven Stability of recombinant consensus interferon to air-jet and ultrasonic nebulization J. Pharm. Sci. 84 1995 1210 1214
16. R.W. Niven, A.Y. Ip, S. Mittelman, S.J. Prestrelski, and T. Arakawa Some factors associated with the ultrasonic nebulization of proteins Pharm. Res. 12 1995 53 59
17. L. Khatri, K.M.G. Taylor, D.Q.M. Craig, and K. Palin An assessment of jet and ultrasonic nebulisers for the delivery of lactate dehydrogenase solutions Int. J. Pharm. 227 2001 121 131
18. J.S. Lass, A. Sant, and M. Knoch New advances in aerosolised drug delivery: vibrating membrane nebuliser technology Exp. Opin. Drug Deliv. 3 2006 693 702
19. J.C. Waldrep, and R. Dhand Advanced nebulizer designs employing vibrating mesh/aperture plate technologies for aerosol generation Curr. Drug Deliv. 5 2008 114 119
20. L. Vecellio The mesh nebuliser: a recent technical innovation for aerosol delivery Breathe 2 2006 252 260
21. A. Hawe, M. Wiggenhorn, M. van de Weert, J.H.O. Garbe, H.-C. Mahler, and W. Jiskoot Forced degradation of therapeutic proteins J. Pharm. Sci. 101 2012 895 913
22. Sylvia Kiese, Astrid Papppenberger, Wolfgang Friess, and Hanns-Christian Mahler Shaken, not stirred: mechanical stress testing of an IgG1 antibody J. Pharm. Sci. 97 2008 4347 4366
23. A. Eppler, M. Weigandt, A. Hanefeld, and H. Bunjes Relevant shaking stress conditions for antibody preformulation development Eur. J. Pharm. Biopharm. 74 2010 139 147
24. S. Dasnoy, N. Dezutter, D. Lemoine, V. Le Bras, and V. Préat High-throughput screening of excipients intended to prevent antigen aggregation at air-liquid interface Pharm. Res. 28 2011 1591 1605
25. P. Sondermann, R. Huber, and U. Jacob Crystal structure of the soluble form of the human Fcg-receptor IIb: a new member of the immunoglobulin superfamily at 1.7 Å resolution EMBO J. 18 1999
26. S. Hertel, T. Pohl, W. Frieß, and G. Winter That's cool! - nebulization of thermolabile proteins with a cooled vibrating mesh nebulizer Eur. J. Pharmaceut. Biopharmaceut. 87 2014 357 365
27. S.P. Hertel, W. Friess, G. Winter, Comparison of aerosol collection methods for liquid protein formulations, in: R.N. Dalby, P.R. Byron, J. Peart, J.D. Suman, P.M. Young (Eds.), RDD Europe 2011, Berlin, 2011, pp. 345-350.
28. R.W. Niven, S.J. Prestrelski, M.J. Treuheit, A.Y. Ip, and T. Arakawa Protein nebulization II. Stabilization of G-CSF to air-jet nebulization and the role of protectants Int. J. Pharm. 127 1996 191 201
29. T. Serno, J.F. Carpenter, T.W. Randolph, and G. Winter Inhibition of agitation-induced aggregation of an IgG-antibody by hydroxypropyl-beta- cyclodextrin J. Pharm. Sci. 99 2009 1193 1206
30. L.B. Salem, C. Bosquillon, L.A. Dailey, L. Delattre, G.P. Martin, B. Evrard, and B. Forbes Sparing methylation of [beta]-cyclodextrin mitigates cytotoxicity and permeability induction in respiratory epithelial cell layers in vitro J. Control. Release 136 2009 110 116
31. L. Matilainen, T. Toropainen, H. Vihola, J. Hirvonen, T. Järvinen, P. Jarho, and K. Järvinen In vitro toxicity and permeation of cyclodextrins in Calu-3 cells J. Control. Release 126 2008 10 16
32. T. Serno, E. Hartl, A. Besheer, R. Miller, and G. Winter The role of polysorbate 80 and HPbetaCD at the air-water interface of IgG solutions Pharm. Res. 30 2013 117 130
33. R. Bhat, and S.N. Timasheff Steric exclusion is the principal source of the preferential hydration of proteins in the presence of polyethylene glycols Protein Sci. 1 1992 1133 1143
34. T. Arakawa, and S.N. Timasheff Mechanism of polyethylene glycol interaction with proteins Biochemistry 24 1985 6756 6762
35. T. Arakawa, D. Ejima, K. Tsumoto, N. Obeyama, Y. Tanaka, Y. Kita, and S.N. Timasheff Suppression of protein interactions by arginine: a proposed mechanism of the arginine effects Biophys. Chem. 127 2007 1 8
36. D. Shukla, and B.L. Trout Interaction of arginine with proteins and the mechanism by which it inhibits aggregation J. Phys. Chem. B 114 2010 13426 13438
37. D. Shah, A.R. Shaikh, X. Peng, and R. Rajagopalan Effects of arginine on heat-induced aggregation of concentrated protein solutions Biotechnol. Prog. 27 2011 513 520
38. M. Luisetti, P. Kroneberg, T. Suzuki, Z. Kadija, B. Muellinger, I. Campo, J. Gleske, G. Rodi, W.C. Zimlich, F. Mariani, F. Ferrari, M. Frey, and B.C. Trapnell Physical properties, lung deposition modeling, and bioactivity of recombinant GM-CSF aerosolised with a highly efficient nebulizer Pulm. Pharmacol. Ther. 24 2011 123 127
39. P. Brand, I. Friemel, T. Meyer, H. Schulz, J. Heyder, and K. Häuβinger Total deposition of therapeutic particles during spontaneous and controlled inhalations J. Pharm. Sci. 89 2000 724 731
40. S.P. Hertel, Pulmonary Delivery of Pharmaceutical Proteins by Means of Vibrating Mesh Nebulization, PhD, Ludwig Maximilian University, Department of Chemistry and Pharmacy, Munich, 2014.